iCAD (ICAD) investor relations material

Executive summary

• Entered into a definitive merger agreement with RadNet, Inc. on April 15, 2025, with expected closing in Q2 or Q3 2025; each iCAD share to be exchanged for 0.0677 RadNet shares.

• Q1 2025 total revenue was $4.9M, nearly flat year-over-year, with ARR up 18% to $10.7M.

• Focused on AI-powered cancer detection, with the ProFound Breast Health Suite driving platform-based SaaS and DaaS growth.

• Gross margin improved to 86% from 83% year-over-year, driven by higher-margin cloud revenues.

• Operating expenses decreased 4% to $5.3M, and net loss narrowed to $0.8M from $1.2M in Q1 2024.

Financial highlights

• Q1 2025 revenue: $4.9M, down from $5.0M in Q1 2024; product revenue up 4.6% to $3.2M, services revenue down 12% to $1.6M.

• Gross profit increased to $4.2M (86% margin) from $4.1M (83% margin) year-over-year.

• Operating loss improved to $(1.1)M from $(1.4)M in Q1 2024.

• Net loss narrowed to $(0.8)M, or $(0.03) per share, compared to $(1.2)M, or $(0.05) per share, in Q1 2024.

• Non-GAAP Adjusted Net Loss was $0.5M ($0.02/share), versus $1.2M ($0.05/share) last year.

Outlook and guidance

• Management expects the merger with RadNet to close in Q2 or Q3 2025, subject to regulatory and shareholder approvals.

• Anticipates continued shift toward subscription and cloud revenue, with marketing efforts aligned to accelerate this transition.

• Liquidity and capital resources deemed sufficient to sustain operations for at least the next 12 months.

• Expects to accelerate innovation and broaden access to AI-powered solutions through the pending RadNet acquisition.